Seedlabs

SLC25A45-Based GLP-1RA Response Diagnostic

A diagnostic test to identify patients who are likely to be resistant to GLP-1 receptor agonist (GLP-1RA) weight-loss drugs based on SLC25A45 genetic variants or expression levels.

Biochemistry, Genetics and Molecular BiologyMetabolism and Genetic Disorders
Endocrinologists and obesity clinics can use this to personalize treatment plans for patients prescribed GLP-1RAs (e.g., Semaglutide), ensuring the drug is only administered to those biologically capable of the required fuel-switching to fatty acid oxidation.
Try the live prototype
slc25a45-based-glp-1ra-9bd1.seedlabs.tech
Open
Explainer video — the idea and its research foundation.

Concept

A precision medicine diagnostic tool that screens for mutations or deficiencies in the SLC25A45 mitochondrial carrier. Because SLC25A45 is essential for carnitine biosynthesis and fatty acid oxidation, individuals with deficiencies in this carrier are resistant to the lipid-mobilizing effects of GLP-1RAs. This test would allow clinicians to identify 'non-responders' before prescribing expensive anti-obesity medications.

Why now

Research shows that SLC25A45 deficiency renders subjects resistant to adipose tissue loss induced by GLP-1RA [1]. Additionally, specific human mutations (such as R285C) are already associated with altered methylated amino acid levels in plasma [0], providing a concrete biological marker for screening.

AI assessment

Backed by 2 papers92

A high-potential precision medicine tool with a clear clinical wedge, though it relies on a narrow genetic mechanism that may only explain a small fraction of non-responders.

Evidence strength
4/5
The idea is directly supported by two specific papers linking SLC25A45 to carnitine biosynthesis and GLP-1RA resistance in mice.
Market pull
5/5
The massive adoption of GLP-1RAs creates an urgent need for clinicians to identify non-responders to avoid wasted cost and ineffective treatment.
Novelty & moat
4/5
Targeting a specific mitochondrial carrier for GLP-1RA response is a novel application of recent basic science that creates a defensible diagnostic moat.
Feasibility
5/5
Developing a genetic screen for a specific mutation (R285C) or a plasma assay for methylated amino acids is technically straightforward and fast to prototype.
Wedge clarity
5/5
The product has a sharp, single-purpose entry point: a companion diagnostic for GLP-1RA prescription.
Simplicity / focus
5/5
The proposal avoids 'platform' creep and focuses exclusively on one diagnostic test for one drug class.

Scored by AI against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity). A prior estimate to compare ideas before real-world signal arrives.

Who benefits

  • Obesity Clinic Patientsindividual

    Avoids the frustration and cost of using a medication that is biologically ineffective for them due to a specific mitochondrial carrier deficiency.

  • Pharmaceutical Companiescompany

    Increases the reported efficacy rates of their GLP-1RA products by identifying and excluding non-responsive genetic subpopulations in clinical trials and real-world use.

Research it builds on

  1. SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis
    Marília M. Dias, Martin King, Engy Shokry et al. · 2025 · 10 citations
  2. Mitochondrial control of fuel switching via carnitine biosynthesis
    Christopher Auger, Hiroshi Nishida, Bo Yuan et al. · 2026 · 7 citations
Leave feedback
feasibility